STAT+: Pharmalittle: We’re reading about another Novartis trial failure, a Novo Nordisk setback, and more

Good morning and welcome to another working week. The weekend respite, longer than usual due to a holiday, provided time for relaxation and rejuvenation. Now, the routine of meetings and deadlines has returned. To combat the daily grind, a cup of stimulation is being enjoyed today – butter pecan flavor. Please join us in this stimulating routine, though no prescription is necessary.

In the world of pharmaceuticals, a couple of recent trials have seen failure. Novartis, a major company, experienced setback with its experimental drug for a rare neuromuscular condition. The drug, del-desiran, failed to improve muscle function in a pivotal study, a second major trial collapse in a short timeframe. This news may raise concerns about the company's pipeline and acquisition strategy as it navigates a major patent cliff.

Despite a recent victory with a multiple sclerosis drug, the stock experienced a decline of up to 10% in early trading in Switzerland.

Novo Nordisk, another major player, has also encountered difficulties. The company halted two trials of its drug, ziltivekimab, which aimed to reduce inflammation and improve cardiovascular health. This decision came after a data monitoring committee found that the trials were unlikely to succeed. The move follows the earlier failure of the drug in the ZEUS trial, which showed no reduction in the risk of major clinical complications, including deaths and heart attacks. For more details, continue to the full story in STAT+.